To date, two kinds of Granulocyte Colony-Stimulating Factors (G-CSF) have been
approved for autologous peripheral blood hematopoietic stem cell (PBSCs) mobilization and posttransplant
hematologic recovery after high-dose chemotherapy: filgrastim (originator and
biosimilar) and lenograstim. Biosimilar filgrastim has been approved on the basis of comparable
efficacy and safety in clinical studies where it has been used as chemotherapy-induced febrile
neutropenia prophylaxis, but no specific pre-registration studies have been published in the
transplant setting. Hence, there is still general skepticism about the role of biosimilar G-CSFs in
this setting of patients. This review of biochemical, pre-clinical and clinical data suggests
significant comparability of biosimilar filgrastim with both originator filgrastim and lenograstim in
autologous PBSCs mobilization and post-autograft hematologic recovery.
Keywords: Autologous stem cell transplant, Biosimilar filgrastim, Hematologic recovery, Lenograstim, Originator
filgrastim, Peripheral blood hematopoietic stem cell mobilization.
Rights & PermissionsPrintExport